Provider: Nature Publishing Group
Content: application/x-research-info-systems
TY  - JOUR

TI  - Hepatitis C[mdash]global prevalence (update)

JO  - World Health Org. Weekly Epidemiol. Rec.

PY  - 2000///

VL  - 75

SP  - 18

EP  - 19

ER  - 



TY  - JOUR

TI  - Consensus Statement on Management of Hepatitis C

JO  - NIH Consens. State Sci. Statements

PY  - 2002///

VL  - 19

SP  - 1

EP  - 46

ER  - 



TY  - JOUR

AU  - Manns, M. P.

TI  - Peginterferon [alpha]-2b plus ribavirin compared with interferon [alpha]-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

JO  - Lancet

PY  - 2001///

VL  - 358

SP  - 958

EP  - 965

M3  - 10.1016/S0140-6736(01)06102-5

N1  - 10.1016/S0140-6736(01)06102-5

UR  - http://dx.doi.org/10.1016/S0140-6736(01)06102-5

ER  - 



TY  - JOUR

AU  - Fried, M. W.

TI  - Peginterferon [alpha]-2a plus ribavirin for chronic hepatitis C virus infection

JO  - N. Engl. J. Med.

PY  - 2002///

VL  - 347

SP  - 975

EP  - 982

M3  - 10.1056/NEJMoa020047

N1  - 10.1056/NEJMoa020047

UR  - http://dx.doi.org/10.1056/NEJMoa020047

ER  - 



TY  - JOUR

AU  - Tan, S.-L.

AU  - Pause, A.

AU  - Shi, Y.

AU  - Sonenberg, N.

TI  - Hepatitis C therapeutics: Current status and emerging strategies

JO  - Nature Rev. Drug Discov.

PY  - 2002///

VL  - 1

SP  - 867

EP  - 881

M3  - 10.1038/nrd937

N1  - 10.1038/nrd937

UR  - http://dx.doi.org/10.1038/nrd937

ER  - 



TY  - JOUR

AU  - Shiffman, M. L.

TI  - A randomized, controlled trial to determine whether continued ribavirin monotherapy in hepatitis C virus-infected patients who responded to interferon[ndash]ribavirin combination therapy will enhance sustained virologic response

JO  - J. Infect. Dis.

PY  - 2001///

VL  - 184

SP  - 405

EP  - 409

M3  - 10.1086/322778

N1  - 10.1086/322778

UR  - http://dx.doi.org/10.1086/322778

ER  - 



TY  - JOUR

AU  - Hoofnagle, J. H.

TI  - Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alpha and ribavirin

JO  - Hepatology

PY  - 2003///

VL  - 38

SP  - 66

EP  - 74

M3  - 10.1053/jhep.2003.50258

N1  - 10.1053/jhep.2003.50258

UR  - http://dx.doi.org/10.1053/jhep.2003.50258

ER  - 



TY  - JOUR

AU  - Lau, J. Y. N.

AU  - Tam, R. C.

AU  - Liang, T. J.

AU  - Hong, Z.

TI  - Mechanism of action of ribavirin in the combination treatment of chronic HCV infection

JO  - Hepatology

PY  - 2002///

VL  - 35

SP  - 1002

EP  - 1009

M3  - 10.1053/jhep.2002.32672

N1  - 10.1053/jhep.2002.32672

UR  - http://dx.doi.org/10.1053/jhep.2002.32672

ER  - 



TY  - JOUR

AU  - Dusheiko, G.

TI  - Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

JO  - J. Hepatol.

PY  - 1996///

VL  - 25

SP  - 591

EP  - 598

M3  - 10.1016/S0168-8278(96)80225-X

N1  - 10.1016/S0168-8278(96)80225-X

UR  - http://dx.doi.org/10.1016/S0168-8278(96)80225-X

ER  - 



TY  - JOUR

AU  - Bodenheimer, H. C.

TI  - Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial

JO  - Hepatology

PY  - 1997///

VL  - 26

SP  - 473

EP  - 477

M3  - 10.1002/hep.510260231

N1  - 10.1002/hep.510260231

UR  - http://dx.doi.org/10.1002/hep.510260231

ER  - 



TY  - JOUR

AU  - Zoulim, F.

TI  - Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients

JO  - J. Viral Hepat.

PY  - 1998///

VL  - 5

SP  - 193

EP  - 198

M3  - 10.1046/j.1365-2893.1998.00099.x

N1  - 10.1046/j.1365-2893.1998.00099.x

UR  - http://dx.doi.org/10.1046/j.1365-2893.1998.00099.x

ER  - 



TY  - JOUR

AU  - Pawlotsky, J.-M.

TI  - Antiviral action of ribavirin in chronic hepatitis C

JO  - Gastroenterology

PY  - 2004///

VL  - 126

SP  - 703

EP  - 714

M3  - 10.1053/j.gastro.2003.12.002

N1  - 10.1053/j.gastro.2003.12.002

UR  - http://dx.doi.org/10.1053/j.gastro.2003.12.002

ER  - 



TY  - JOUR

AU  - McHutchison, J. G.

TI  - Interferon [alpha]-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C

JO  - N. Engl. J. Med.

PY  - 1998///

VL  - 339

SP  - 1485

EP  - 1492

M3  - 10.1056/NEJM199811193392101

N1  - 10.1056/NEJM199811193392101

UR  - http://dx.doi.org/10.1056/NEJM199811193392101

ER  - 



TY  - JOUR

AU  - Reichard, O.

TI  - Randomized, double-blind, placebo-controlled trial of interferon [alpha]-2b with and without ribavirin for chronic hepatitis C

JO  - Lancet

PY  - 1998///

VL  - 351

SP  - 83

EP  - 87

M3  - 10.1016/S0140-6736(97)06088-1

N1  - 10.1016/S0140-6736(97)06088-1

UR  - http://dx.doi.org/10.1016/S0140-6736(97)06088-1

ER  - 



TY  - JOUR

AU  - Poynard, T.

TI  - Randomized trial of interferon [alpha]2b plus ribavirin for 48 weeks or for 24 weeks versus interferon [alpha]2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus

JO  - Lancet

PY  - 1998///

VL  - 352

SP  - 1426

EP  - 1432

M3  - 10.1016/S0140-6736(98)07124-4

N1  - 10.1016/S0140-6736(98)07124-4

UR  - http://dx.doi.org/10.1016/S0140-6736(98)07124-4

ER  - 



TY  - JOUR

AU  - Lanford, R. E.

TI  - Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(I)-poly(C), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons

JO  - J. Virol.

PY  - 2003///

VL  - 77

SP  - 1092

EP  - 1104

M3  - 10.1128/JVI.77.2.1092-1104.2003

N1  - 10.1128/JVI.77.2.1092-1104.2003

UR  - http://dx.doi.org/10.1128/JVI.77.2.1092-1104.2003

ER  - 



TY  - JOUR

AU  - Contreras, A. M.

AU  - Viral, R. N. A.

TI  - mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system

JO  - J. Virol.

PY  - 2002///

VL  - 76

SP  - 8505

EP  - 8517

M3  - 10.1128/JVI.76.17.8505-8517.2002

N1  - 10.1128/JVI.76.17.8505-8517.2002

UR  - http://dx.doi.org/10.1128/JVI.76.17.8505-8517.2002

ER  - 



TY  - JOUR

AU  - Young, K.-C.

TI  - Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy

JO  - Hepatology

PY  - 2003///

VL  - 38

SP  - 869

EP  - 878

M3  - 10.1053/jhep.2003.50445

N1  - 10.1053/jhep.2003.50445

UR  - http://dx.doi.org/10.1053/jhep.2003.50445

ER  - 



TY  - JOUR

AU  - Lanford, R. E.

TI  - Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes

JO  - J. Virol.

PY  - 2001///

VL  - 75

SP  - 8074

EP  - 8081

M3  - 10.1128/JVI.75.17.8074-8081.2001

N1  - 10.1128/JVI.75.17.8074-8081.2001

UR  - http://dx.doi.org/10.1128/JVI.75.17.8074-8081.2001

ER  - 



TY  - JOUR

AU  - Hong, Z.

TI  - The role of ribavirin-induced mutagenesis in HCV therapy: A concept or a fact?

JO  - Hepatology

PY  - 2003///

VL  - 38

SP  - 807

EP  - 810

M3  - 10.1053/jhep.2003.50464

N1  - 10.1053/jhep.2003.50464

UR  - http://dx.doi.org/10.1053/jhep.2003.50464

ER  - 



TY  - JOUR

AU  - Crotty, S.

AU  - Cameron, C. E.

AU  - Andino, R.

TI  - RNA virus error catastrophe: Direct molecular test by using ribavirin

JO  - Proc. Natl Acad. Sci. USA

PY  - 2001///

VL  - 98

SP  - 6895

EP  - 6900

M3  - 10.1073/pnas.111085598

N1  - 10.1073/pnas.111085598

UR  - http://dx.doi.org/10.1073/pnas.111085598

ER  - 



TY  - JOUR

AU  - Neumann, A. U.

TI  - Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-[alpha] therapy

JO  - Science

PY  - 1998///

VL  - 282

SP  - 103

EP  - 107

M3  - 10.1126/science.282.5386.103

N1  - 10.1126/science.282.5386.103

UR  - http://dx.doi.org/10.1126/science.282.5386.103

ER  - 



TY  - JOUR

AU  - Layden-Almer, J. E.

AU  - Ribeiro, R. M.

AU  - Wiley, T.

AU  - Perelson, A. S.

AU  - Layden, T. J.

TI  - Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin

JO  - Hepatology

PY  - 2003///

VL  - 37

SP  - 1343

EP  - 1350

M3  - 10.1053/jhep.2003.50217

N1  - 10.1053/jhep.2003.50217

UR  - http://dx.doi.org/10.1053/jhep.2003.50217

ER  - 



TY  - JOUR

AU  - Herrmann, E.

AU  - Lee, J.-H.

AU  - Marison, G.

AU  - Modi, M.

AU  - Zeuzem, S.

TI  - Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon

JO  - Hepatology

PY  - 2003///

VL  - 37

SP  - 1351

EP  - 1358

M3  - 10.1053/jhep.2003.50218

N1  - 10.1053/jhep.2003.50218

UR  - http://dx.doi.org/10.1053/jhep.2003.50218

ER  - 



TY  - JOUR

AU  - Glue, P.

TI  - The clinical pharmacology of ribavirin

JO  - Semin. Liv. Dis.

PY  - 1999///

VL  - 19

SP  - 17

EP  - 24

ER  - 



TY  - GEN

PY  - ///

ER  - 



TY  - JOUR

AU  - Tsuboto, A.

TI  - Viral dynamics and pharmacokinetics in combined interferon [alpha]-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load

JO  - Intervirology

PY  - 2002///

VL  - 45

SP  - 33

EP  - 42

M3  - 10.1159/000050085

N1  - 10.1159/000050085

UR  - http://dx.doi.org/10.1159/000050085

ER  - 



TY  - JOUR

AU  - Neumann, A. U.

TI  - Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus

JO  - J. Infect. Dis.

PY  - 2000///

VL  - 182

SP  - 28

EP  - 35

M3  - 10.1086/315661

N1  - 10.1086/315661

UR  - http://dx.doi.org/10.1086/315661

ER  - 



TY  - JOUR

AU  - McHutchison, J. G.

TI  - The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C

JO  - Gastroenterology

PY  - 2000///

VL  - 119

SP  - 1317

EP  - 1323

ER  - 



TY  - JOUR

AU  - Powers, K. A.

TI  - Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon [alpha]-2b

JO  - Semin. Liv. Dis.

PY  - 2003///

VL  - 23

SP  - 13

EP  - 18

M3  - 10.1055/s-2003-41630

N1  - 10.1055/s-2003-41630

UR  - http://dx.doi.org/10.1055/s-2003-41630

ER  -